Knight Therapeutics Financials

GUD Stock  CAD 6.18  0.09  1.44%   
You can make use of Knight Therapeutics fundamental data analysis to find out if markets are presently mispricing the entity. We were able to break down twenty-three available fundamentals for Knight Therapeutics, which can be compared to its peers in the industry. The stock experiences a somewhat bearish sentiment, but the market may correct it shortly. Check odds of Knight Therapeutics to be traded at C$5.99 in 90 days. Key indicators impacting Knight Therapeutics' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.05830.0622
Notably Down
Pretty Stable
Current Ratio3.393.5669
Notably Down
Slightly volatile
  
Understanding current and past Knight Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Knight Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Knight Therapeutics' assets may result in an increase in income on the income statement.

Knight Therapeutics Stock Summary

Knight Therapeutics competes with Stella Jones, Richelieu Hardware, Element Fleet, ECN Capital, and Winpak. Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company was incorporated in 2013 and is headquartered in Montreal, Canada. KNIGHT THERAPEUTICS operates under Drug ManufacturersSpecialty Generic classification in Canada and is traded on Toronto Stock Exchange.
Foreign Associate
  USA
Specialization
Healthcare, Drug Manufacturers - Specialty & Generic
InstrumentCanada Stock View All
ExchangeToronto Exchange
Business Address3400 de Maisonneuve
SectorPharmaceuticals
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.knighttx.com
Phone514 484 4483
CurrencyCAD - Canadian Dollar
You should never invest in Knight Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Knight Stock, because this is throwing your money away. Analyzing the key information contained in Knight Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Knight Therapeutics Key Financial Ratios

Knight Therapeutics' financial ratios allow both analysts and investors to convert raw data from Knight Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Knight Therapeutics over time and compare it to other companies across industries.

Knight Therapeutics Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets1.0B991.9M1.1B945.5M1.1B952.1M
Net Debt(173.4M)(45.0M)6.0M10.3M11.9M12.5M
Cash229.6M86.0M71.7M58.8M52.9M50.2M
Total Current Assets554.6M307.3M395.6M365.1M419.9M556.5M
Common Stock694.4M628.9M599.1M540.0M621.1M625.0M
Other Current Liab1.3M2.0M15.0M7.9M9.1M8.6M
Retained Earnings174.5M191.6M161.8M150.9M173.5M178.6M
Accounts Payable44.5M65.3M106.1M85.4M98.2M103.1M
Net Receivables82.0M67.4M110.2M98.2M113.0M118.6M
Good Will77.7M75.4M82.3M79.8M91.8M74.0M
Inventory56.5M72.4M92.5M91.8M105.6M110.9M
Other Current Assets4.8M4.5M1.7M20.6M23.7M13.2M
Total Liab153.4M149.9M229.0M198.6M228.4M130.2M
Short Term Debt53.6M28.3M20.3M19.6M22.5M22.7M
Intangible Assets156.5M350.3M338.8M290.0M333.5M350.1M

Knight Therapeutics Key Income Statement Accounts

202020212022202320242025 (projected)
Interest Expense3.4M3.6M6.6M12.5M11.2M9.4M
Total Revenue199.5M243.5M293.6M328.2M377.4M396.3M
Gross Profit81.7M115.4M138.1M107.6M123.8M129.9M
Operating Income(3.4M)(5.3M)(2.4M)6.4M7.4M7.8M
Ebit(3.4M)(5.3M)(2.4M)6.4M7.4M7.8M
Research Development11.7M12.7M14.8M17.5M20.2M21.2M
Ebitda28.6M42.6M60.2M56.8M65.3M68.6M
Income Before Tax32.1M6.7M(44.0M)(22.0M)(19.8M)(18.8M)
Net Income31.8M15.7M(29.9M)(16.8M)(15.2M)(14.4M)
Income Tax Expense325K(9.0M)(14.1M)(5.2M)(4.6M)(4.4M)
Cost Of Revenue117.8M128.1M155.5M220.6M253.7M266.4M

Knight Therapeutics Key Cash Accounts

202020212022202320242025 (projected)
Change To Inventory9.7M(17.2M)(11.4M)698K628.2K659.6K
Change In Cash55.3M(143.6M)(14.3M)(12.9M)(11.6M)(11.0M)
Free Cash Flow(32.9M)(179.6M)14.7M18.5M16.7M17.5M
Depreciation32.1M47.9M62.6M50.4M58.0M60.9M
Other Non Cash Items(54.4M)(15.0M)33.0M29.7M34.2M35.9M
Capital Expenditures20.7M224.2M25.8M10.0M11.5M10.9M
Net Income31.8M15.7M(29.9M)(16.8M)(15.2M)(14.4M)
End Period Cash Flow229.6M86.0M71.7M58.8M52.9M50.2M

Knight Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Knight Therapeutics's current stock value. Our valuation model uses many indicators to compare Knight Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Knight Therapeutics competition to find correlations between indicators driving Knight Therapeutics's intrinsic value. More Info.
Knight Therapeutics is one of the top stocks in price to earning category among its peers. It also is rated as one of the top companies in revenue category among its peers totaling about  2,451,075  of Revenue per Price To Earning. At this time, Knight Therapeutics' Total Revenue is very stable compared to the past year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Knight Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Knight Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Knight Therapeutics Systematic Risk

Knight Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Knight Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Knight Therapeutics correlated with the market. If Beta is less than 0 Knight Therapeutics generally moves in the opposite direction as compared to the market. If Knight Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Knight Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Knight Therapeutics is generally in the same direction as the market. If Beta > 1 Knight Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.

Knight Therapeutics Total Assets Over Time

Today, most investors in Knight Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Knight Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Knight Therapeutics growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.81

At this time, Knight Therapeutics' Price Earnings To Growth Ratio is very stable compared to the past year.

Knight Therapeutics March 23, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Knight Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Knight Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Knight Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Knight Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Knight Therapeutics's daily price indicators and compare them against related drivers.

Other Information on Investing in Knight Stock

Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.